



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Prescription Monitoring Program (PMP) Annual Report

Fiscal Year 2024-2025

July 1, 2025

Introduction

Act 676 of the 2006 Louisiana Legislature authorized the development, implementation, and operation of an electronic system for the monitoring of controlled substances and drugs of concern that are dispensed within the state or to state residents by pharmacies located in other states. The goal of the program is to improve the state's ability to identify and inhibit the diversion of controlled substances and drugs of concern in an efficient and cost-effective manner that shall not impede the appropriate utilization of these drugs for legitimate medical purposes.

The Louisiana Prescription Monitoring Program (PMP) was implemented in August 2008. Pharmacies and dispensing prescribers were instructed how and when to transmit their dispensing transactions to the program vendor for assimilation into the PMP database. Prescribers, dispensers, and other persons authorized by law to access PMP information were instructed how to secure their access privileges. The web portal to the PMP database was opened to searches and requests on January 1, 2009, and the program remains fully operational.

Advisory Council

The enabling legislation created the PMP Advisory Council to assist the Board in the development and operation of the program. The council consists of the following members, each of whom may appoint a designee:

1. The president of the Louisiana State Board of Medical Examiners;
2. The president of the Louisiana State Board of Dentistry;
3. The president of the Louisiana State Board of Nursing;
4. The president of the Louisiana State Board of Optometry Examiners;
5. The president of the Louisiana Academy of Physician Assistants;
6. The president of the Louisiana Board of Pharmacy;
7. The superintendent of the Louisiana State Police;
8. The administrator of the United States Drug Enforcement Administration;
9. The speaker of the Louisiana House of Representatives;
10. The president of the Louisiana Senate;
11. The chairman of the House Committee on Health and Welfare;
12. The chairman of the Senate Committee on Health and Welfare;
13. The secretary of the Department of Health;
14. The president of the Louisiana State Medical Society;
15. The president of the Louisiana Dental Association;
16. The president of the Louisiana Association of Nurse Practitioners;
17. The president of the Optometry Association of Louisiana;
18. The president of the Louisiana Pharmacists Association;
19. The president of the Louisiana Independent Pharmacies Association;
20. The president of the National Association of Chain Drug Stores;
21. The president of the Louisiana Sheriffs' Association;
22. The president of the Louisiana District Attorneys Association;
23. The president of the Pharmaceutical Research and Manufacturers of America;
24. The president of the Louisiana Academy of Medical Psychologists.

During Fiscal Year 2024-2025, the council convened a quorum of members on February 5, 2025. The program staff presented a variety of statistical information including the number of prescription transactions reported to the program database as well as the number of searches and requests for information to the database by prescribers, dispensers, law enforcement, prosecutorial officials, and specialty courts. The staff also reported on the PMP InterConnect® interstate data sharing network, as well as the increased utilization by the private sector of the PMP Gateway® service, which offers interoperability of the PMP with existing practice information systems in a variety of settings, including hospitals, clinics, practitioner offices, and pharmacies.

Program Highlights – FY25

- **August 20, 2024** – In accordance with Act 393 of the 2023 Louisiana Legislature, the Board of Pharmacy completed the rulemaking process and adopted LAC 46:LIII.2905 to provide for conducting open public meetings via electronic means and participation in open meeting via electronic means for people with disabilities.
- **October 1, 2024** - Act 246 of the 2024 Louisiana Legislature places all mifepristone and misoprostol containing products in Louisiana Schedule IV. Pharmacies and other dispensers of mifepristone and misoprostol prescriptions are required to report their eligible prescription transactions to the PMP due to the scheduling action.
- **December 3, 2024** – Louisiana Department of Health (LDH) provided additional federal grant money to continue funding the Gateway® PMP Statewide Integration Project for the time period October 1, 2024 through June 30, 2025.
- **January 1, 2025** - Act 693 of the 2024 Louisiana Legislature transferred the Board of Pharmacy's regulatory authority for therapeutic marijuana to LDH. Marijuana pharmacy permits transitioned to marijuana retail permits and with that transition the Act removed the requirement to report sales information to the PMP.
- **February 3, 2025** – Louisiana PMP began interstate data sharing of PMP information through PMP InterConnect® with the New York Prescription Monitoring Program.
- **June 30, 2025** – as of this date, the Louisiana PMP participates in interstate data sharing of PMP information with 38 PMPs: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, D.C., Military Health System – Dept. of Defense (MHS-DOD), Florida, Georgia, Idaho, Indiana, Iowa, Kansas, Kentucky, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nevada, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Virginia and West Virginia.

Louisiana PMP Statewide Integration Project

On January 1, 2019, the Board partnered with the Louisiana Department of Health's Office of Public Health, Bureau of Community Preparedness (LDH-OPH-BCP) and Bamboo Health to provide a statewide PMP integration option to all healthcare providers in Louisiana utilizing a service called PMP Gateway®. Gateway® offers healthcare providers an option to integrate PMP data within the provider's electronic health record (EHR) or pharmacy information system to provide a streamlined clinical workflow for providers. The integration eliminates the need for providers to log in separately to the PMP web portal; instead, the EHR automatically initiates a patient query and returns the patient's PMP information directly within the provider's EHR or pharmacy information system.

The statewide initiative has been funded through grants obtained from LDH-OPH-BCP which has covered the costs from January 1, 2019 through June 30, 2025.

As of June 30, 2025, the Louisiana PMP was interoperable with 789 licensees (EHRs and pharmacy management systems) across the state. The 789 licensees represent more than 3,100 facilities in Louisiana and were responsible for 3,908,565 PMP requests in the month of June 2025.

Program Metrics

The data on the following pages provide summary data for the operational aspects of the program for Calendar Year 2024. The first graphic presents information about the use of the information by authorized prescribers, pharmacists, and their delegates. Data for the different roles of users are presented, including the number authorized to obtain PMP access privileges, the number with active access privileges, and the number of queries to the PMP database through the PMP website (AWARxE®) and through the integration component (Gateway®). The graphic also contains information about the use of the information by other authorized users, including law enforcement, prosecutorial officials, specialty courts, regulatory agencies, and other roles.

The second graphic presents information concerning the numbers of controlled substance prescriptions dispensed in the state, including summary data for different types of drugs like opioids and benzodiazepines. Just over 14.4 million prescriptions for controlled substances and drugs of concern were dispensed in the state during Calendar Year 2024, with an average of 2.776 prescriptions per Louisiana resident. Specifically looking at opioid prescriptions, the state saw a reduction in the number of opioid prescriptions dispensed by 3% compared to Calendar Year 2023.

Calendar Year 2024 PMP User Statistics

PMP User Stats for 2024 (01/01/2024 - 12/31/2024)				
PMP Healthcare Provider Role	Number of Providers Eligible for PMP Access (as of 12/31/2024)	Number of Providers with Active PMP Access Privileges (as of 12/31/2024)	Number of PMP Requests by Providers through AWARxE® During 2024	Number of PMP Requests by Providers through Gateway® During 2024
Physician (MD, DO)	13,956	9,661	2,277,321	27,799,392
Nurse Practitioner (APRN)	5,666	4,565	1,081,564	2,707,411
Dentist (DDS)	2,318	1,518	21,341	8,495
Physician Assistant (PA)	1,480	1,178	215,872	404,853
Optometrist (OD)	374	149	29	17
Podiatrist (DPM)	167	122	8,002	0
Medical Psychologist (MP)	99	91	28,546	37,011
Medical Intern/Resident	1,860	1,379	62,530	980,395
Prescriber's Delegate	N/A	3,050	719,195	N/A
Pharmacist (PST)	9,952	5,588	5,290,356	14,694,451
Pharmacist's Delegate	N/A	1,500	369,498	N/A
Totals	35,872	28,801	10,074,254	46,632,025

Law Enforcement, Prosecutorial Officials & Specialty Courts	Calendar Year 2024 Searches
DEA (Patient Requests)	308
Specialty Court	270
FBI	23
Homeland Security	0
Local Law Enforcement	93
Multijurisdictional Task Force	0
State Attorney General	0
State Police	52
OIG	7
Totals	753

Regulatory Agencies	CY 2024 Searches
Board of Pharmacy	3656
Board of Dentistry	9
Board of Medicine	864
Board of Nursing	16
Board of Optometry Investigator	0
DEA(Licensee/Registrant Request)	401
Totals	4,946

Other Roles	Searches
Medical Examiner/Coroner & Delegates	728
Louisiana Medicaid Program	121
Totals	849


State Rx per Capita
2.776

Prescriptions
14,481,690

Quantity Dispensed

each (tablets, kits, etc.)	585,300K
grams (solids)	4,098K
milliliters (liquids)	102,797K
UNSPECIFIED	0K

Days Supply
316,812,567




Schedule

Schedule	Prescriptions (#) by Drug Schedule
2	2024: 4,658,053
3	2024: 911,531
4	2024: 3,663,161
5	2024: 498,299
*	2024: 4,750,646


Prescriptions (#) by Drug Classes

Drug Class	2024
Opioid	3,463,270
Benzo	2,089,039
Anxiolytic, Hypnotics, Se...	1,260,617
Other	7,668,764


Prescriptions >= 90 MME vs. All




Rx by Prescriber Environment



New vs. Refill Prescriptions



Opioids vs. Non Opioids (%)



Disclaimer: Appriss is the sole owner of all intellectual property rights in and to the Appriss Property. "Appriss Property" means all of the following: (i) the AWARxE Service and any user guides or manuals related thereto; (ii) any deliverables and/or work product developed while providing the AWARxE Service; (iii) enhancements, modifications or derivative works to the AWARxE Service; and (iv) any patient consolidation identifier mechanisms and other data fields source from a third party.

Conclusion

On December 31, 2024, the program completed sixteen years of operation, marked by significant improvements and sustained functionality. Feedback from authorized users indicates that the program is a resource-efficient and cost-effective solution. Consistent trends in the data suggest measurable progress in reducing the diversion of controlled substances.

We are grateful for the continued partnership and meaningful contributions from members of the Prescription Monitoring Program Advisory Council. We also acknowledge the contributions from our administrative coordinators, Ms. Reshmi Ravindranath, Ms. Amy Hammon, Ms. Christina Howland, and Ms. Nerissa Montgomery for their assistance with the development of this report and administrative oversight of the program.

Respectfully submitted,

Joe Fontenot
Executive Director